Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 14.33% and Operating profit at -3.91% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 7.46% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 14.33% and Operating profit at -3.91% over the last 5 years
3
Negative results in Sep 25
4
With ROE of 2.05%, it has a expensive valuation with a 1.79 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,033 Million (Small Cap)
88.00
NA
0.65%
1.05
1.83%
1.69
Revenue and Profits:
Net Sales:
963 Million
(Quarterly Results - Sep 2025)
Net Profit:
7 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.87%
0%
8.87%
6 Months
2.71%
0%
2.71%
1 Year
-4.79%
0%
-4.79%
2 Years
-0.04%
0%
-0.04%
3 Years
-41.68%
0%
-41.68%
4 Years
-32.35%
0%
-32.35%
5 Years
-51.5%
0%
-51.5%
Shenzhen Sunnypol Optoelectronics Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.33%
EBIT Growth (5y)
-3.91%
EBIT to Interest (avg)
4.90
Debt to EBITDA (avg)
3.52
Net Debt to Equity (avg)
0.83
Sales to Capital Employed (avg)
0.59
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
38.23%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.50%
ROE (avg)
7.46%
Valuation key factors
Factor
Value
P/E Ratio
88
Industry P/E
Price to Book Value
1.79
EV to EBIT
63.84
EV to EBITDA
21.14
EV to Capital Employed
1.40
EV to Sales
2.14
PEG Ratio
NA
Dividend Yield
0.61%
ROCE (Latest)
2.20%
ROE (Latest)
2.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
963.50
874.40
10.19%
Operating Profit (PBDIT) excl Other Income
15.30
89.50
-82.91%
Interest
15.20
15.10
0.66%
Exceptional Items
2.70
2.70
Consolidate Net Profit
7.00
8.30
-15.66%
Operating Profit Margin (Excl OI)
15.90%
37.70%
-2.18%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 10.19% vs 8.59% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -15.66% vs -71.77% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,581.50
2,061.30
25.24%
Operating Profit (PBDIT) excl Other Income
261.40
164.70
58.71%
Interest
37.20
32.50
14.46%
Exceptional Items
0.20
1.50
-86.67%
Consolidate Net Profit
68.40
42.90
59.44%
Operating Profit Margin (Excl OI)
33.70%
13.60%
2.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 25.24% vs -5.06% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 59.44% vs -79.80% in Dec 2023
About Shenzhen Sunnypol Optoelectronics Co., Ltd. 
Shenzhen Sunnypol Optoelectronics Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






